山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (2): 41-47.doi: 10.6040/j.issn.1671-7554.0.2020.1628
薛源1,林雪艳2,徐歌1,田永杰1
XUE Yuan1, LIN Xueyan2, XU Ge1, TIAN Yongjie1
摘要: 目的 研究低氧诱导因子-1α(HIF-1α)在子宫内膜异位症(EMS)患者血清中的表达水平及诊断价值,探讨HIF-1α对EMS在位子宫内膜间质细胞上皮-间质转化(EMT)的影响。 方法 采用ELISA法对EMS(36例,EMS组)和子宫肌瘤(43例,对照组)患者血清的HIF-1α水平进行测量分析,其中EMS组患者临床分期I期、Ⅱ期为EMS轻度组,Ⅲ期、Ⅳ期为EMS重度组。采用受试者工作特征(ROC)曲线以及曲线下面积(AUC)反应HIF-1α的诊断水平。取EMS在位子宫内膜分离培养提取原代间质细胞,干扰HIF-1α表达的慢病毒和空白病毒分别转染该细胞,得到sh-HIF-1α和sh-NC两组细胞,采用Western blotting法测量EMT相关分子(N-Cadherin、vimentin、Slug)的表达;Transwell法对比两组细胞的迁移、侵袭能力;流式细胞术检测两组细胞的凋亡率。 结果 EMS组与对照组比较,其血清HIF-1α表达水平明显增高(P<0.001);其ROC曲线及AUC结果显示HIF-1α对EMS具有一定的诊断效力,子宫内膜增生期与分泌期所对应的血清HIF-1α表达差异无统计学意义(P=0.593),EMS重度组患者血清HIF-1α含量显著高于EMS轻度组(P<0.001)。sh-HIF-1α组细胞的N-Cadherin(P=0.013)、vimentin(P=0.045)、Slug(P=0.038)表达均降低,细胞迁移、侵袭力减弱(P均<0.001),凋亡率升高(P=0.013)。 结论 HIF-1α在EMS患者血清中表达水平明显升高,可作为一项潜在的临床诊断指标;HIF-1α可能通过调控EMT过程影响EMS的发生发展。
中图分类号:
[1] 郎景和. 对子宫内膜异位症认识的历史、现状与发展[J]. 中国实用妇科与产科杂志, 2020, 36(3): 193-196. [2] Song WW, Gui AP, Li W, et al. Expressions of HIF-1α and KISS-1 in patients with liver cancer and correlation analysis[J]. Eur Rev Med Pharmacol Sci, 2017, 21(18): 4058-4063. [3] Chen L, Shi Y, Yuan J, et al. HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy[J]. PLoS ONE, 2014, 9(3): e90678. doi: 10.1371/journal.pone.0090678. [4] Mansour RN, Enderami SE, Ardeshirylajimi A, et al. Evaluation of hypoxia inducible factor-1 alpha gene expression in colorectal cancer stages of Iranian patients[J]. J Canc Res Ther, 2016, 12(4): 1313-1317. [5] Mccluggage WG. Endometriosis-related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions: Endometriosis-related pathology[J]. Histopathology, 2020, 76(1): 76-92. [6] Moradi M, Parker M, Sneddon A, et al. The endometriosis impact questionnaire(EIQ): a tool to measure the long-term impact of endometriosis on different aspects of womens lives[J]. BMC Womens Health, 2019, 19(1): 64. doi: 10.1186/s12905-019-0762-x. [7] Yovich JL, Rowlands PK, Lingham S, et al. Pathogenesis of endometriosis: look no further than John Sampson[J]. Reprod Biomed Online, 2020, 40(1): 7-11. [8] Tavcar J, Loring M, Movilla PR, et al. Diagnosing endometriosis before laparoscopy: radiologic tools to evaluate the disease[J]. Curr Opin Obstet Gynecol, 2020, 32(4): 292-297. [9] Zhan L, Wang W, Zhang Y, et al. Hypoxia-inducible factor-1alpha: a promising therapeutic target in endometriosis[J]. Biochimie, 2016, 123(4): 130-137. [10] Asby DJ, Cuda F, Hoakwie F, et al. HIF-1 promotes the expression of its α-subunit via an epigenetically regulated transactivation loop[J]. Mol Biosyst, 2014, 10(10): 2505-2508. [11] Karakus S, Sancakdar E, Akkar O, et al. Elevated serum CD95/FAS and HIF-1α levels, but not Tie-2 levels, may be biomarkers in patients with severe endometriosis: a preliminary report[J]. J Minim Invasive Gynecol, 2016, 23(4): 573-577. [12] Cai F F, Xu C, Pan X, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer[J]. Oncotarget, 2016, 7(47): 77793-77806. [13] Swartz JE, Pothen AJ, Stegeman I, et al. Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review[J]. Cancer Med, 2015, 4(7): 1101-1116. [14] Jason J, Christiansen, Ayyappan K, et al. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis[J]. Cancer Res, 2006, 66(17): 8319-8326. [15] Yang YM, Yang WX. Epithelial-to-mesenchymal transition in the development of endometriosis[J]. Oncotarget, 2017, 8(25): 41679-41689. [16] Konrad L, Dietze R, Riaz MA, et al. Epithelial-mesenchymal transition in endometriosis—when does it happen?[J]. J Clin Med, 2020, 9(6): 1915. doi: 10.3390/jcm9061915. [17] 周明利, 卢先州, 张树友. HIF-1α与EMT在肿瘤中的作用及意义研究进展[J]. 中国普通外科杂志, 2012, 21(9): 1132-1136. ZHOU Mingli, LU Xianzhou, ZHANG Shuyou. Role of HIF-1α and EMT in tumor progression[J]. Chinese Journal of General Surgery, 2012, 21(9): 1132-1136. [18] Bartley J, Licher A, Hotz B, et al. Epithelial to mesenchymal transition(EMT)seems to be regulated differently in endometriosis and the endometrium[J]. Arch Gynecol Obstet, 2014, 289(4): 871-881. [19] 林雪艳, 李春艳, 侯小满, 等. PARP-1及EMT标志物在子宫腺肌病在位及异位内膜中的表达[J]. 山东大学学报(医学版), 2017, 55(9): 36-40. LIN Xueyan, LI Chunyan, HOU Xiaoman, et al. Expression of PARP-1 and EMT markers in eutopic and ectopic endometrium of adenomyosis[J]. Journal of Shandong University(Health Science), 2017, 55(9): 36-40. [20] Liu CY, Lin HH, Tang MJ, et al. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation[J]. Oncotarget, 2015, 6(18): 15966-15983. [21] Xin L, Zhao R, Lei J, et al. SND1 acts upstream of SLUG to regulate the epithelial - mesenchymal transition(EMT)in SKOV3 cells[J]. Faseb J, 2019, 33(3): 3795-3806. [22] Li W, Zong S, Shi Q, et al. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin[J]. Sci Rep, 2016, 6: 37534. doi: 10.1038/srep37534. [23] Wang F, Chang M, Shi Y, et al. Down-regulation of hypoxia-inducible factor-1 suppresses malignant biological behavior of triple-negative breast cancer cells[J]. Int J Clin Exp Med, 2014, 7(11): 3933-3940. [24] He GD, Jiang Y, Zhang B, et al. The effect of HIF-1α on glucose metabolism, growth and apoptosis of pancreatic cancerous cells[J]. Asia Pac J Clin Nutr, 2014, 23(1): 174-180. [25] Lv F, Du R, Shang W, et al. HIF-1α silencing inhibits the growth of osteosarcoma cells by inducing apoptosis[J]. Ann Clin Lab Sci, 2016, 46(2): 140-146. [26] Li HY, Jia YF, Wang YS, et al. Targeting HIF-1α signaling pathway for gastric cancer treatment[J]. Die Pharmazie, 2019, 74(1): 3-7. [27] Qiu SP, Li HL, Shi HL, et al. Notoginsenoside Ft1 down-regulates HIF-1α, inhibits cell proliferation, decreases migration and promotes apoptosis in breast cancer cells[J]. Acta Pharm Sin, 2016, 51(7): 1091-1097. |
[1] | 鹿向东 杨伟 徐广明 曲元明. 脑膜瘤中PPAR-γ的表达及曲格列酮对脑膜瘤培养细胞生长的影响[J]. 山东大学学报(医学版), 2209, 47(6): 65-. |
[2] | 赵舸,邹存华,宋冬冬,赵淑萍. 丹参酮IIA对子宫内膜癌细胞增殖与凋亡的影响[J]. 山东大学学报 (医学版), 2022, 60(9): 53-58. |
[3] | 颜磊,岳彩欣,刘懿淳. 子宫内膜异位症的生育力保护[J]. 山东大学学报 (医学版), 2022, 60(9): 31-34. |
[4] | 冷金花,史精华. 子宫腺肌病的临床表现[J]. 山东大学学报 (医学版), 2022, 60(7): 1-5. |
[5] | 陈忠绍,褚然,李明宝,张向宁. MRKH综合征相关腹股沟子宫疝修补术后腹壁瘢痕子宫内膜异位症1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(5): 114-117. |
[6] | 林雪艳,张灿灿,田民乐,田永杰. 聚腺苷酸二磷酸核糖聚合酶-1在子宫内膜异位症中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(2): 27-31. |
[7] | 封海岗,刘国文,曹洪. 干扰MAD2L1基因表达对乳腺癌细胞凋亡的影响及机制[J]. 山东大学学报 (医学版), 2022, 60(10): 9-16. |
[8] | 单婧,王晓秋,李大金. NK细胞参与子宫内膜异位症及其不孕的分子机制[J]. 山东大学学报 (医学版), 2021, 59(8): 8-13. |
[9] | 卢游,且迪,伍晋辉,杨凡. 干预Sonic Hedgehog信号通路对宫内发育迟缓新生大鼠学习记忆能力的影响[J]. 山东大学学报 (医学版), 2021, 59(5): 82-89. |
[10] | 梁炎春,叶海花,陆丽美,戴郁菁,程谦益,蔡婉玲,曾涵秋,陈杏欢,王兴,韦雅婧,杨如玉. 慢性子宫内膜炎对子宫内膜异位症相关性不孕妊娠结局的影响[J]. 山东大学学报 (医学版), 2021, 59(3): 55-59. |
[11] | 潘虹江,王焕昇,裴发军,杨明山. 孤立性膀胱子宫内膜异位症1例[J]. 山东大学学报 (医学版), 2021, 59(2): 122-124. |
[12] | 王国云,王凯,袁明,陈子江. 子宫内膜异位症立体化管理体系(山东方案)[J]. 山东大学学报 (医学版), 2021, 59(10): 1-16. |
[13] | 王宝金,赵欣欣,李霞,马倩,王新月,孙阳,史中娜. miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭[J]. 山东大学学报 (医学版), 2020, 58(12): 23-28. |
[14] | 史丽,马静,赵喜娃,关英霞,赵连梅,单保恩. miR-25-3p在40例子宫内膜腺癌组织中的表达及对KLE细胞生物学功能的影响[J]. 山东大学学报 (医学版), 2020, 58(12): 86-91. |
[15] | 张晓璐,王丽莉,陈凯明,娄宪芝,张曼. 组蛋白去乙酰化酶SIRT1经Toll样受体4途径对巨噬细胞凋亡的调控[J]. 山东大学学报 (医学版), 2020, 58(12): 8-14. |
|